Insulin Delivery Device - Market Insights, Competitive Landscape, and Market Forecast - 2034

Insulin Delivery Device Market Summary

Overview

• The global insulin delivery device market was valued at USD 20.4 billion in 2025 and is projected to reach USD 42.8 billion by 2034.
• The market is expected to expand at a CAGR of 8.6% during the forecast period 2026-2034, supported by the rising global prevalence of diabetes, the accelerating shift toward automated insulin delivery and closed-loop systems, growing adoption of smart and connected insulin pens, and the expanding indications of leading device platforms to insulin-requiring type 2 diabetes populations.
• By product type, the insulin pens segment dominated the insulin delivery device market with a 43% share in 2025.
• By system type, conventional (open-loop) insulin delivery accounted for the largest share of the market in 2025, while automated insulin delivery (AID) systems represented the fastest-growing system type.
• By diabetes type, the type 2 diabetes segment dominated the insulin delivery device market with a 58% share in 2025, reflecting the much larger global type 2 patient population, while type 1 diabetes continues to account for the majority of insulin pump and AID system usage.
• By end-user, the homecare settings segment dominated the insulin delivery device market with a 66% share in 2025.
• North America accounted for the largest share of the insulin delivery device market at 36% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Insulin delivery devices are medical tools used to administer insulin to people with diabetes, since insulin cannot be taken orally and must be delivered into subcutaneous tissue. The scope encompasses insulin pens, including reusable pens such as Novo Nordisk's NovoPen 6 and Eli Lilly's Tempo Pen, disposable prefilled pens such as Novo Nordisk's FlexTouch, Eli Lilly's KwikPen, and Sanofi's SoloStar, and smart or connected pens such as Medtronic's InPen and Novo Nordisk's NovoPen Echo Plus; insulin pumps, including tethered or durable pumps such as Medtronic's MiniMed platform, Tandem Diabetes Care's t: slim X2 and Tandem Mobi, Ypsomed's YpsoPump, and SOOIL's DANA pumps, and patch or tubeless pumps such as Insulet's Omnipod, EOFLOW's EOPatch, and CeQur's Simplicity; automated insulin delivery (AID) systems that bundle a pump, continuous glucose monitor, and dosing algorithm, including Medtronic's MiniMed 780G, Tandem's Control-IQ+ platform, Insulet's Omnipod 5, and Beta Bionics' iLet Bionic Pancreas; insulin syringes from Becton Dickinson, Terumo, and Owen Mumford; and insulin jet injectors and needle-free delivery systems. The market spans homecare, hospital, and diabetes clinic settings across type 1 and type 2 diabetes populations.

Insulin Delivery Device Market Key Growth Drivers

• Rising global prevalence of diabetes, with an estimated 591 million people living with diabetes in 2025 and this figure projected to approach 854 million by 2050, sustaining broad-based demand for insulin administration devices.
• Accelerating shift toward automated insulin delivery (AID) and closed-loop systems that bundle pump, continuous glucose monitoring, and dosing algorithms to reduce patient burden and improve glycemic control.
• Growing adoption of smart and connected insulin pens that provide dose logging, insulin-on-board calculation, and continuous glucose monitor integration for patients on multiple daily injections.
• Expanding regulatory indications of leading device platforms to insulin-requiring type 2 diabetes populations, pregnancy, and pediatric age groups, broadening the eligible patient base.
• Rising preference for home-based diabetes management that favors self-administered, discreet, and connected insulin delivery devices over hospital-based insulin therapy.
• Increasing patient education and awareness initiatives from diabetes associations and healthcare providers that drive earlier adoption of advanced insulin delivery technology.
• Ongoing product innovation and competitive launch activity among leading manufacturers, including next-generation patch pumps, tubeless AID systems, and interoperable automated insulin dosing components.

Key Companies in Insulin Delivery Device Market

The leading participants in the insulin delivery device market include the following:

• Medtronic plc
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Ypsomed Holding AG
• Becton, Dickinson and Company
• Beta Bionics, Inc.
• Terumo Corporation

Factors Contributing to the Growth of the Insulin Delivery Device Market

Market Drivers

Rising Global Prevalence of Diabetes

The foundational driver of the insulin delivery device market is the rising global prevalence of diabetes, with an estimated 591 million people living with diabetes worldwide in 2025 and this figure projected to rise to approximately 854 million by 2050, a 46% increase. More than 90% of these cases are type 2 diabetes, and a growing share of this population requires insulin therapy as oral medications and other therapies become insufficient over the course of disease progression. As the global diabetic population continues to expand, driven by aging populations, rising obesity prevalence, and urbanization, the base of patients requiring regular and precise insulin administration grows correspondingly, sustaining demand across the full range of insulin delivery device categories throughout the forecast period.

Accelerating Shift Toward Automated Insulin Delivery Systems

The accelerating shift toward automated insulin delivery (AID) and closed-loop systems is reshaping the competitive and technological center of gravity of the insulin delivery device market. Systems including Medtronic's MiniMed 780G, Insulet's Omnipod 5, Tandem's Control-IQ+ platform, and Beta Bionics' iLet Bionic Pancreas integrate continuous glucose monitoring data with automated dosing algorithms to adjust insulin delivery in real time, reducing the burden of manual dosing decisions and improving time-in-range outcomes. In March 2024, the FDA cleared the Sequel Twist AID system, the first automated insulin delivery system to directly measure the volume and flow of delivered insulin, enhancing detection of blockages and delivery issues. As clinical evidence continues to demonstrate the glycemic and quality-of-life benefits of AID systems, and as regulatory clearances expand the eligible patient population, demand for AID technology grows as the fastest-growing system type across the forecast period.

Market Restraints

The insulin delivery device market faces several interrelated restraints that temper its growth. The continued availability and clinical effectiveness of oral antidiabetic medications for a substantial share of the type 2 diabetes population delays the transition to injectable or pump-based insulin therapy for many patients. An increased number of device-related product recalls in recent years has raised safety and reliability concerns among patients, clinicians, and regulators, and has required manufacturers to invest in quality system improvements. High device and consumable costs, combined with limited insurance reimbursement in many geographies outside North America and Western Europe, constrain adoption of advanced pumps, AID systems, and smart pens, particularly in price-sensitive and lower-resource markets. Recently implemented tariffs on imported medical devices and components in the United States have increased production costs for manufacturers reliant on global supply chains, a cost pressure that may be passed through to patients and could reduce access to advanced insulin delivery devices, particularly among patients with limited insurance coverage. The steep learning curve associated with advanced pump and AID system technology can limit adoption among older patients and those less comfortable with connected digital health tools. The lack of full interoperability between devices from different manufacturers, despite regulatory frameworks intended to support interoperable automated insulin dosing components, continues to limit patient choice and system flexibility. Together, these factors moderate the pace of adoption and require vendors to demonstrate reliability, affordability, and ease of use to sustain growth.

Insulin Delivery Device Market Segment Analysis

The global insulin delivery device market is segmented by product type (insulin pens [reusable, disposable/prefilled, and smart/connected], insulin pumps [tethered/durable and patch/tubeless], insulin syringes, insulin jet injectors, and others), by system type (automated insulin delivery (AID)/closed-loop systems and conventional/open-loop insulin delivery), by diabetes type (type 1 diabetes and type 2 diabetes), by end-user (homecare settings, hospitals, diabetes and specialty clinics, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product Type

Dominant Subsegment: Insulin Pens.

The insulin pens category is expected to dominate the market. The insulin pens segment accounted for a 43% share of the insulin delivery device market in 2025. Insulin pens, spanning reusable pens such as Novo Nordisk's NovoPen 6, disposable prefilled pens such as Eli Lilly's KwikPen and Sanofi's SoloStar, and smart connected pens such as Medtronic's InPen and Novo Nordisk's NovoPen Echo Plus, are the leading product category because pens remain the most widely prescribed insulin delivery method globally, particularly among the much larger type 2 diabetes population and in emerging markets where pump therapy penetration remains limited. The dominance of the segment reflects the breadth of pen options across price points and features, and the sustained global volume of prefilled pen prescriptions, even as smart and connected pens represent the fastest-growing pen subcategory. While insulin pumps, syringes, and jet injectors are substantial and, in the case of patch and AID-integrated pumps, faster-growing categories, particularly within the type 1 diabetes population, the breadth of global pen prescribing and the scale of the type 2 diabetes population sustain the leadership of the segment across the forecast period.

By System Type

Dominant Subsegment: Conventional (Open-Loop) Insulin Delivery.

Conventional, open-loop insulin delivery, encompassing standard pens, syringes, and manually programmed insulin pumps without integrated automated dosing algorithms, accounted for the largest share of the insulin delivery device market in 2025, reflecting the scale of the installed base of pen and syringe users worldwide who are not candidates for or have not yet adopted pump therapy. Automated insulin delivery (AID) systems, including Medtronic's MiniMed 780G, Insulet's Omnipod 5, Tandem's Control-IQ+ platform, and Beta Bionics' iLet Bionic Pancreas, represented the fastest-growing system type in 2025, as expanding regulatory indications, growing clinical evidence of glycemic benefit, and continued device miniaturization drive adoption beyond the historical type 1 diabetes core market. As AID systems continue to expand into type 2 diabetes, pediatric, and pregnancy indications, the system type segmentation is expected to shift progressively toward automated delivery, even as conventional delivery methods retain the larger share of overall device volume by unit count across the forecast period.

Insulin Delivery Device Market Region Analysis

Dominant Region: North America

North America accounted for a 36% share of the global insulin delivery device market in 2025, representing the highest regional market share globally. The leadership of the region reflects the high burden of diabetes, with more than 38 million people, or 11.6% of the United States population, living with diabetes according to the Centers for Disease Control and Prevention, combined with a robust healthcare infrastructure and strong adoption of innovative medical technologies. The United States is the largest national market, supported by high healthcare expenditure, favorable reimbursement policies for advanced pumps, AID systems, and smart pens, and the concentration of leading manufacturers including Medtronic, Insulet, Tandem Diabetes Care, and Beta Bionics. The concentration of vendors, reimbursement maturity, and diabetes prevalence reinforce the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region faces a rapidly escalating diabetes burden driven by urbanization, increasingly sedentary lifestyles, and evolving dietary habits, with China and India at the forefront; recent estimates indicate that 77 million people over the age of 18 in India live with type 2 diabetes, with an additional 25 million considered prediabetic. China, Japan, and India are the principal national markets, supported by expanding healthcare infrastructure, government-led diabetes awareness and early diagnosis campaigns, and the growing presence of global manufacturers establishing local partnerships and pursuing regulatory approvals tailored to regional affordability needs. As diagnosis rates rise and modern insulin delivery devices become more accessible and affordable, the region increases its adoption of insulin delivery devices from a growing base, positioning Asia-Pacific as the fastest-growing regional market across the forecast period.

Regional Commentary

North America

North America leads the market, supported by high diabetes prevalence, a mature healthcare infrastructure, favorable reimbursement, and the concentration of leading device manufacturers. The United States dominates the region through its concentration of manufacturers, healthcare expenditure, and diabetes awareness programs.

Europe

Europe is a significant market shaped by robust healthcare infrastructure, rising diabetes prevalence approaching 60 million people in 2024 and projected to reach 72.4 million by 2050 according to the International Diabetes Federation, and favorable reimbursement policies that support adoption of reusable pens, insulin pumps, and smart devices. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the region continues to be a hub for regulatory innovation, exemplified by Medtronic's 2025 CE Mark label expansion for the MiniMed 780G system.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by a rapidly escalating diabetes burden, expanding healthcare infrastructure, and increasing government investment in diabetes awareness and early diagnosis across China, Japan, and India.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as diabetes prevalence rises and healthcare infrastructure expands, though adoption of advanced insulin delivery devices remains concentrated in leading urban centers and private healthcare systems.

Insulin Delivery Device Market Competitive Landscape

The global insulin delivery device market is classified as Consolidated. A small group of established medical technology and pharmaceutical companies holds the majority of the market through comprehensive portfolios spanning pens, pumps, and AID systems, supported by digital platforms that connect devices to mobile applications and cloud-based data systems. Competition centers on the breadth of the automated insulin delivery portfolio, integration with continuous glucose monitoring ecosystems, device miniaturization and tubeless form factors, and the ability to secure regulatory approvals and insurance reimbursement across major markets. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Consolidated, with Medtronic, Insulet, Tandem Diabetes Care, Novo Nordisk, Sanofi, Eli Lilly, Roche, and Ypsomed collectively dominating the market, alongside specialist and regional vendors including Becton Dickinson, Beta Bionics, Terumo, Abbott, CeQur, EOFLOW, and Biocon.
• Leading players: Medtronic and Insulet lead in automated insulin delivery systems through the MiniMed 780G and Omnipod 5 platforms, respectively; Tandem Diabetes Care leads in tethered pump miniaturization through the Tandem Mobi; Novo Nordisk, Eli Lilly, and Sanofi lead in global insulin pen volume; and Beta Bionics leads in autonomous, algorithm-driven closed-loop delivery through the iLet Bionic Pancreas.
• Geographic reach: Medtronic, Novo Nordisk, Sanofi, and Eli Lilly operate global commercial and regulatory organizations, while specialist vendors including Beta Bionics, CeQur, and EOFLOW maintain more concentrated footprints centered on specific regions and device categories.
• Product portfolio strength: Competitive advantage rests on the breadth across pens, pumps, and AID systems, and on the integration of devices with continuous glucose monitoring ecosystems and mobile health platforms.
• Pipeline strength: Development is concentrated in tubeless and miniaturized AID systems, interoperable automated insulin dosing components, and smart pen and CGM interoperability.
• Strategic partnerships: Collaboration spans CGM integration partnerships, exemplified by Insulet's compatibility agreement for the Abbott FreeStyle Libre 2 Plus sensor with Omnipod 5, and Abbott's collaboration with Medtronic linking its CGM platform to Medtronic's insulin pump ecosystem.
• M&A activity: Consolidation has shaped the field, exemplified by Novo Nordisk's acquisition of Biocorp to strengthen its connected insulin pen portfolio and Abbott's acquisition of Bigfoot Biomedical, a developer of smart insulin management systems.
• Innovation focus: Innovation is concentrated in tubeless and miniaturized AID systems, direct insulin flow measurement technology such as the Sequel Twist system, and interoperable, algorithm-driven closed-loop platforms.
• Regulatory standing: FDA clearance and CE Mark approval, particularly for automated insulin dosing system components and expanded pediatric, pregnancy, and type 2 diabetes indications, are decisive competitive credentials across this consolidated, innovation-driven market.

Insulin Delivery Device Market Recent Developmental Activities

• In July 2025, Medtronic received CE Mark approval to expand the indicated population for its MiniMed 780G automated insulin delivery system to include individuals as young as two years old, pregnant women, and people with insulin-requiring type 2 diabetes. Strategic significance: the expansion broadened Medtronic's addressable AID market beyond its historical type 1 diabetes core base.
• In May 2025, GO-Pen ApS received FDA 510(k) clearance for the GO-PEN, a user-filled reusable insulin pen compatible with standard insulin vials. Strategic significance: the clearance introduced a more affordable and sustainable alternative to traditional prefilled disposable pens.

Insulin Delivery Device Market Segmentation

Insulin Delivery Device Market Assessment by Product Type

• Insulin Pens
• Reusable Insulin Pens
• Disposable/Prefilled Insulin Pens
• Smart/Connected Insulin Pens
• Insulin Pumps
• Tethered/Durable Pumps
• Patch/Tubeless Pumps
• Insulin Syringes
• Insulin Jet Injectors
• Others

Insulin Delivery Device Market Assessment by System Type

• Automated Insulin Delivery (AID)/Closed-Loop Systems
• Conventional (Open-Loop) Insulin Delivery

Insulin Delivery Device Market Assessment by Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes

Insulin Delivery Device Market Assessment by End-User

• Homecare Settings
• Hospitals
• Diabetes and Specialty Clinics
• Others

Insulin Delivery Device Market Assessment by Geography

• North America
• United States Insulin Delivery Device Market Size in USD million (2023-2034)
• Canada Insulin Delivery Device Market Size in USD million (2023-2034)
• Mexico Insulin Delivery Device Market Size in USD million (2023-2034)
• Europe
• Germany Insulin Delivery Device Market Size in USD million (2023-2034)
• United Kingdom Insulin Delivery Device Market Size in USD million (2023-2034)
• France Insulin Delivery Device Market Size in USD million (2023-2034)
• Italy Insulin Delivery Device Market Size in USD million (2023-2034)
• Spain Insulin Delivery Device Market Size in USD million (2023-2034)
• Rest of Europe Insulin Delivery Device Market Size in USD million (2023-2034)
• Asia-Pacific
• China Insulin Delivery Device Market Size in USD million (2023-2034)
• Japan Insulin Delivery Device Market Size in USD million (2023-2034)
• India Insulin Delivery Device Market Size in USD million (2023-2034)
• Australia Insulin Delivery Device Market Size in USD million (2023-2034)
• South Korea Insulin Delivery Device Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Insulin Delivery Device Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Insulin Delivery Device Market Size in USD million (2023-2034)
• Africa Insulin Delivery Device Market Size in USD million (2023-2034)
• South America Insulin Delivery Device Market Size in USD million (2023-2034)

Key Takeaways from the Insulin Delivery Device Market Report Study

• Market size analysis for the current insulin delivery device market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product and technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global insulin delivery device market.
• Various opportunities available for competitors in the insulin delivery device market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current insulin delivery device market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for insulin delivery device market growth in the future?

Target audience who can benefit from this insulin delivery device market report study

• Insulin delivery device and diabetes technology providers
• Research organizations and consulting companies
• Diabetes and endocrinology-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in insulin delivery devices
• Various end-users who want to know more about the insulin delivery device market and the latest technological developments in the insulin delivery device market.

Frequently Asked Questions

Q1. At what rate is the insulin delivery device market expected to grow?

The global insulin delivery device market is projected to grow at a compound annual growth rate of 8.6% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the insulin delivery device market?

The global insulin delivery device market was valued at USD 20.4 billion in 2025 and is projected to reach USD 42.8 billion by 2034.

Q3. Which region dominates the insulin delivery device market?

North America dominated the insulin delivery device market with a 36% share in 2025, driven by high diabetes prevalence, a mature healthcare infrastructure, and the concentration of leading manufacturers. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by a rapidly escalating diabetes burden and expanding healthcare infrastructure across China, Japan, and India.

Q4. What are the key factors driving growth in the insulin delivery device market?

The principal drivers are the rising global prevalence of diabetes; the accelerating shift toward automated insulin delivery and closed-loop systems; growing adoption of smart and connected insulin pens; expanding regulatory indications to insulin-requiring type 2 diabetes, pregnancy, and pediatric populations; and rising preference for home-based diabetes management.

Q5. Who are the major players in the insulin delivery device market?

The market is consolidated and led by Medtronic plc, Insulet Corporation, and Tandem Diabetes Care, Inc., alongside Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed Holding AG, Becton, Dickinson and Company, Beta Bionics, Inc., and Terumo Corporation.

This product will be delivered within 2 business days.